Loading company…
Normunity develops immuno-oncology medicines designed to restore immune activity against cancer.
Founded in 2021 and based in Connecticut, Normunity develops precision immuno-oncology medicines. Its pipeline targets mechanisms that limit immune cell activity against cancer, including a lead monoclonal antibody program. In January 2025, it raised USD 75 million in Series B funding co-led by Samsara BioCapital and Enavate Sciences, with Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group, Connecticut Innovations, Regeneron Ventures, Pfizer Venture Investments, and YK Bioventures participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in